Terrible News for Pfizer Stock Investors
The past three years have been challenging for (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, they have been insufficient. And recent regulatory developments in the U.S. somewhat complicate things for the drugmaker.
Here's what investors need to know.
Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from Comirnaty, its COVID-19 vaccine, and Paxlovid, its therapy for the disease, started dropping off a cliff. However, Pfizer's coronavirus franchise has remained critical to its overall financial results. In 2024, the company's combined revenue from Paxlovid and Comirnaty was $11.1 billion.
Source Fool.com
Pfizer Inc. Stock
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 40 € there is a hugely positive potential of 88.37% for Pfizer Inc. compared to the current price of 21.24 €.
